Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Open in API
Filings indexed 338 across all filing types
Latest filing 2024-06-05 Regulatory Filings
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2024-06-05 English
Addex Convenes Annual General Meeting 2024
AGM Information Classification · 99% confidence The document explicitly announces that the company's "2024 Annual General Meeting will take place on Friday June 28, 2024," and proceeds to list the detailed agenda items for that meeting. Key agenda items include the 'Approval of the Annual Report,' 'Re-elections of the members of the Board of Directors,' and 'Amendments to the Articles of Association.' This content is characteristic of materials distributed in preparation for or as part of an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2024-06-05 English
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Report Publication Announcement Classification · 99% confidence The document is a press release announcing that Addex Therapeutics "will issue its Q1 2024 Financial Results on June 6, 2024" and will host a teleconference/webcast to discuss them. It provides details for joining the call and webcast registration links, but it does not contain the actual financial results themselves (which would typically be an Earnings Release (ER) or Interim Report (IR)). According to Rule 2, when a document announces the publication of a report and provides details for an associated event (like a conference call), it fits the definition of a Report Publication Announcement (RPA).
2024-05-31 English
Addex to Present at Bio€quity Europe 2024
Regulatory Filings Classification · 96% confidence The document is a press release dated May 8, 2024, announcing that the CEO will present at the BioEquity Europe 2024 conference on May 13, 2024. It details the time, location, and topic (corporate update). This type of announcement, which informs investors about participation in an industry conference or presentation, is best classified as an Investor Presentation (IP) if it were the presentation itself, or more accurately, a general announcement related to investor relations activities. Since it is an announcement about an upcoming presentation/corporate update at a conference, it falls under the general scope of investor communications. However, none of the specific codes perfectly match a 'Conference Presentation Announcement'. Given the options, 'Investor Presentation (IP)' is the closest fit for content related to corporate updates presented to investors, although this is an announcement *about* a presentation, not the presentation itself. The 'Menu vs Meal' rule suggests that if it were an announcement of a report, it would be RPA/RNS. Since this is an announcement of a corporate update presentation, and not a formal regulatory filing or financial report, 'IP' (Investor Presentation) is the most contextually relevant category for the subject matter being communicated to investors, even if it's just the schedule.
2024-05-08 English
FORM 6-K
Regulatory Filings
2024-04-29 English
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Legal Proceedings Report Classification · 99% confidence The document is titled "Ad Hoc Announcement Pursuant to Art. 53 LR" and is dated April 29, 2024. It announces top-line data from a Phase 2 epilepsy study for a drug candidate (ADX71149), stating that the primary endpoint was not met. This format—a press release announcing clinical trial results, safety data, and future plans regarding a specific drug program—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific announcement of financial/operational results (clinical trial outcome) rather than a general regulatory filing fallback (RNS) or a comprehensive quarterly report (IR), the most appropriate classification is Earnings Release (ER), as these announcements often precede or substitute for a formal earnings report when significant operational news breaks. The document length (7740 chars) is substantial enough to be more than just a brief notification of publication (RPA).
2024-04-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.